---
title: "Acurx Pharmaceuticals (ACXP.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ACXP.US/norm.md"
symbol: "ACXP.US"
name: "Acurx Pharmaceuticals"
parent: "https://longbridge.com/en/quote/ACXP.US.md"
datetime: "2026-06-13T23:19:23.145Z"
locales:
  - [en](https://longbridge.com/en/quote/ACXP.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACXP.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACXP.US/norm.md)
---

# Acurx Pharmaceuticals (ACXP.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.6200 | -0.7279 | -1.23 | -1.89 | -2.15 |
| ROE | -109.49% | -141.78% | -221.32% | -305.73% | -587.51% |
| Revenue | - | - | - | - | - |
| Net income | -1.68M | -1.58M | -1.99M | -2.25M | -2.15M |
| Operating income | -1.72M | -1.62M | -2.03M | -2.27M | -2.15M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 9.54M | 7.69M | 6.11M | 6.16M | 4.81M |
| Leverage | 1.36 | 1.46 | 1.68 | 1.73 | 2.08 |
| BVPS | 2.07 | 2.24 | 2.02 | 2.43 | 2.06 |
| Turnover | - | - | - | - | - |
| Cash & STI | 9.25M | 7.56M | 5.91M | 6.06M | 4.64M |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | - | - | - |
| Net debt | -9.25M | -7.56M | -5.91M | -6.06M | -4.64M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -1.41M | -1.18M | -1.88M | -1.67M | -2.05M |
| Investing CF | - | - | - | - | - |
| Financing CF | 3.11M | 2.83M | 1.72M | 3.09M | 2.99M |
| Free CF | -1.12M | -617162.00 | -1.20M | -929027.00 | -1.69M |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |